Endoscopic Scissors Cutting Nasobiliary Duct VS Bilateral Plastic Stent
Launched by FIRST PEOPLE'S HOSPITAL OF HANGZHOU · Oct 24, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different methods for treating a condition known as malignant hilar biliary duct stenosis, which is a type of blockage in the bile ducts often caused by cancer. The researchers want to see if using endoscopic scissors to cut the nasobiliary duct is more effective and safe compared to placing plastic stents to help with this blockage. The trial is currently recruiting participants aged 18 to 80 who have been diagnosed with this condition and need a specific procedure called ERCP to relieve the blockage.
To be eligible, participants need to have a confirmed diagnosis of malignant hilar biliary duct stenosis and meet certain health criteria. Those with severe organ issues, recent infections, or who have had other biliary treatments may not qualify. If you decide to participate, you can expect to undergo the procedure while being closely monitored for safety and effectiveness. The goal is to find the best approach to help patients with this challenging condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients over 18 years old and under 80 years old who were planned to carry out ERCP for malignant hilar biliary duct stenosis
- • 2. Clinically and pathologically confirmed malignant hilar biliary duct stenosis
- • 3. MRCP determines Bismuth classification: II-IV type
- • 4. Comply with research procedures and sign the informed consent form
- Exclusion Criteria:
- • 1. The patient has multiple organ dysfunction and cannot tolerate endoscopic treatment
- • 2. The patient has undergone biliary drainage (endoscopic, percutaneous, or surgical)
- • 3. The patient is currently suffering from cholangitis
- • 4. The patient is participating in other clinical trials
- • 5. Inability to provide informed consent
About First People's Hospital Of Hangzhou
First People's Hospital of Hangzhou is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong focus on patient-centered care, the hospital integrates cutting-edge medical technology with a team of experienced professionals to enhance treatment outcomes. Committed to scientific excellence, the institution actively collaborates with researchers and pharmaceutical companies to facilitate the development of new therapies and improve clinical practices. Its state-of-the-art facilities and commitment to ethical standards make First People's Hospital of Hangzhou a pivotal player in the landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Jianfeng Yang, Doctor
Principal Investigator
First People's Hospital of Hangzhou
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported